Common measurements for modified adeno-associated viruses (AAVs), a gene therapy delivery method, showed substantial ...

Roche has exercised its option to license a novel capsid from Dyno Therapeutics for use in a gene therapy program for an ...

According to the scientists of the National Research University "BelSU", the obtained results allow us to conclude that the ...

National Institute of Standards and Technology scientists looked at multiple techniques used to measure the modified viruses ...

Explore our new AAV Titer ELISA and AAV Antibody Assay Kits, designed for exceptional specificity, sensitivity, and accuracy ...

The capsid license follows an agreement between Dyno and Roche originally announced in May 2020 and marks Dyno’s first adeno-associated virus (AAV) capsid licensing and partnership completion.

The results come from five patients enrolled in the biotech's ingoing phase 1/2 study of RGX-111 – which uses an adeno-associated viral vector (AAV9) to deliver a gene coding for an enzyme that ...

Matika Bio partners with Childs Cure to develop gene therapy vectors for children Matika Bio collaborates with Childs Cure to ...

Currently, the DMD treatment landscape includes Sarepta’s Elevidys (delandistrogene moxeparvovec), the first FDA-approved ...

Gene therapy firm Capsida Biotherapeutics is advancing the first of its AbbVie-partnered neurodegenerative disease therapies ...